BDA: COVID-19 measures affecting clinical trials submissions

BDA: COVID-19 measures affecting clinical trials submissions

The Bulgarian Drug Agency (BDA) announced on March 10, 2021, further measures related to the risk of COVID-19. For the duration of the extraordinary epidemic situation declared by the state, the BDA will accept the documentation required for clinical trial applications and applications for substantial amendments to be submitted on digital media only (CD/DVD). However, […]

BDA: further measures related to COVID-19

BDA: further measures related to COVID-19

The Bulgarian Drug Agency (BDA) announced on March 24, 2020 further measures related to the risk of COVID-19. The measures mainly concern the flow of communication with the agency. The primary aim is to encourage remote submissions and to reduce the number of visits to the administrative department and the reception desk. CESP was already […]